APEIRON Biologics AG Employee Directory
Biotechnology ResearchWien, Austria2-10 Employees
APEIRON Biologics AG is a privately held European biotechnology company based in Vienna, Austria, focused on the discovery and development of treatments for respiratory diseases and novel cancer immunotherapies. The company maintains a balanced portfolio that includes one product on the market, APN311 (Dinutuximab beta, Qarziba), which received EU marketing approval in May 2017 for pediatric neuroblastoma and has been out-licensed globally to EUSA Pharma Ltd with exclusive rights. APEIRON emphasizes its strong patent portfolio and collaboration model, with development projects supported by partnerships with leading global pharmaceutical companies and academic institutions. The organization operates with a small workforce of 2–10 employees and is located at 5 Campus-vienna-biocenter Wien, Alsergrund, Wien 1030, Austria. In July 2024, Ligand Pharmaceuticals announced the acquisition of APEIRON Biologics AG for $100 million.